Christopher Posner - 01 Feb 2024 Form 4 Insider Report for Cara Therapeutics, Inc. (CARA)

Signature
/s/ Darren DeStefano, Attorney-in-Fact
Issuer symbol
CARA
Transactions as of
01 Feb 2024
Transactions value $
-$2,740
Form type
4
Filing time
05 Feb 2024, 16:26:05 UTC
Previous filing
03 Nov 2023
Next filing
12 Feb 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CARA Common Stock Award $0 +62.5K +38.01% $0.00 227K 01 Feb 2024 Direct F1
transaction CARA Common Stock Sale -$2.74K -4.98K -2.2% $0.55 222K 01 Feb 2024 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares that vested under a performance-based restricted stock unit award (the "Award") granted on March 1, 2023 based on the Issuer's satisfaction of certain performance criteria of the Award. In light of the performance-based vesting conditions of the Award, such shares were not reportable under Section 16 until vesting was determined. On February 1, 2024, the Compensation Committee of the Issuer's Board of Directors certified a 50% level of achievement against the Award's performance goals.
F2 This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.
F3 The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $0.55 to $0.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.